<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531295</url>
  </required_header>
  <id_info>
    <org_study_id>University of Utah #00100155</org_study_id>
    <nct_id>NCT02531295</nct_id>
  </id_info>
  <brief_title>Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study</brief_title>
  <official_title>Immunologic Response to Euphorbia Kansui Extract Powder Prepared as Tea in HIV-infected Antiretroviral Therapy (ART)-Suppressed Individuals: a Dose Escalation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>amfAR, The Foundation for AIDS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and bioactivity of an herbal supplement&#xD;
      called &quot;kansui,&quot; which contains several active ingredients such as ingenols that may have a&#xD;
      role in helping clear HIV from the body. Kansui has been used in traditional Chinese medicine&#xD;
      for centuries to treat various ailments such as for eliminating excess fluid in the abdomen&#xD;
      or lungs, loosening phlegm from the chest, and relieving constipation. Based on preliminary&#xD;
      in vitro data from our group, kansui extract powder is a potent activator of HIV&#xD;
      transpcription in latently infected Jurkat cells. The investigators' hypothesis is that&#xD;
      kansui extract powder prepared as tea will be safe and well-tolerated, elicit an in vivo&#xD;
      immunologic response, and at the doses administered, increase HIV transcription in&#xD;
      latently-infected cells among HIV-infected patients on suppressive antiretroviral therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Millions HIV-infected individuals are now receiving life-saving antiretroviral therapy (ART).&#xD;
      However, mortality remains high, particularly in resource-limited countries. Chronic&#xD;
      HIV-infected individuals demonstrate evidence of persistent immune activation despite ART,&#xD;
      which is an independent predictor of mortality in this setting. Given the current absence of&#xD;
      an effective HIV vaccine, finding a cure for HIV will have a large impact on the long-term&#xD;
      health of treated HIV-infected individuals. The key challenge of HIV eradication strategies&#xD;
      is the persistence of a small pool of resting memory CD4+ T cells that harbor latent&#xD;
      replication-competent HIV, untouched by current ART. One potential strategy to eliminate this&#xD;
      reservoir in a &quot;shock and kill&quot; approach in which latency reactivating agents (LRAs) are used&#xD;
      to &quot;shock&quot; the virus out of these cells in order for the host immune response, ART, and/or&#xD;
      additional immunomodulatory agents to then kill the virus-expressing cells. The goal of the&#xD;
      current study is to evaluate the safety and in vivo biological response to an herbal&#xD;
      supplement used in traditional Chinese medicine (&quot;kansui)&quot; that has potent in vitro latency&#xD;
      reactivating capabilities. Kansui is an inexpensive, readily available herbal supplement&#xD;
      prescribed for thousands of years in traditional Chinese medicine and contains active&#xD;
      compounds such as ingenols that have been shown to reverse latency in an animal model. A&#xD;
      semi-synthetic form of ingenol has been shown to potently reactivate latent simian&#xD;
      immunodeficiency virus (SIV) in rhesus macaques and is currently undergoing early drug&#xD;
      development. Though kansui has been studied extensively in traditional Chinese medicine, this&#xD;
      herbal supplement has never been evaluated for biologic activity in HIV disease using Western&#xD;
      scientific research methods. This pilot clinical trial will generate preliminary results&#xD;
      regarding the safety and in vivo biologic activity of kansui. Promising results from this&#xD;
      study may allow future larger studies which can evaluate the efficacy of this&#xD;
      non-pharmacologic agent in the treatment of HIV disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Temporary pause on non-COVID clinical trial recruitment at study site&#xD;
  </why_stopped>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Euphorbia kansui extract powder prepared as tea assessed by the number of grade 2 or higher severity adverse events or drug-related laboratory abnormalities that exceed a frequency of 5%</measure>
    <time_frame>31 days</time_frame>
    <description>The number of grade 2 or higher severity adverse events (AEs) or drug-related laboratory abnormalities that exceed a frequency of 5% over a 31 day study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early T cell immune activation (%CD69+ CD4+ and CD8+ T cells)</measure>
    <time_frame>31 days</time_frame>
    <description>The change in early immune activation levels (as measured by the %CD69+ CD4+ and CD8+ T cells) over a 31 day study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell immune activation (%CD38+HLA-DR+ CD4+ and CD8+ T cells)</measure>
    <time_frame>31 days</time_frame>
    <description>The change in immune activation levels (as measured by the %CD38+HLADR+ CD4+ and CD8+ T cells) over a 31 day study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV reservoir size (cell-associated HIV RNA)</measure>
    <time_frame>31 days</time_frame>
    <description>The change in HIV reservoir size (as measured by cell-associated HIV RNA levels) over a 31 day study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV reservoir size (plasma HIV RNA)</measure>
    <time_frame>31 days</time_frame>
    <description>The change in HIV reservoir size (as measured by ultra-sensitive plasma HIV RNA levels) over a 31 day study period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>HIV</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Kansui 1g per day x 1 day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 1 daily dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kansui 1g per day x 2 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 2 consecutive daily doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kansui 1g per day x 3 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will be given 1 g of Euphorbia kansui extract powder prepared as tea for a total of 3 consecutive daily doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Euphorbia kansui extract powder prepared as tea</intervention_name>
    <description>1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily</description>
    <arm_group_label>Kansui 1g per day x 1 day</arm_group_label>
    <arm_group_label>Kansui 1g per day x 2 days</arm_group_label>
    <arm_group_label>Kansui 1g per day x 3 days</arm_group_label>
    <other_name>Kansui</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed HIV-1 infection in adults aged 18 years or older.&#xD;
&#xD;
          2. Continuous therapy with a DHHS recommended/alternative combination ART for least 36&#xD;
             months (at least 3 agents) at study entry with no regimen changes in the preceding 24&#xD;
             weeks.&#xD;
&#xD;
          3. Maintenance of undetectable plasma HIV-1 RNA (&lt;40 copies/ml) for at least 36 months.&#xD;
             Episodes of single HIV plasma RNA 50-500 copies.ml will not exclude participation if&#xD;
             subsequent HIV plasma RNA is &lt;40 copies/ml.&#xD;
&#xD;
          4. Two CD4+ T cell counts &gt;350 cells/Î¼l in the six months prior to screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-ART viral load &lt;2000 copies/ml (HIV controllers)&#xD;
&#xD;
          2. Based on prior history and/or virologic testing, no alternative ART regimens are&#xD;
             available in the event that the current ART regimen is compromised as a result of this&#xD;
             study.&#xD;
&#xD;
          3. Recent hospitalization in the last 90 days.&#xD;
&#xD;
          4. Recent infection in the last 90 days requiring systemic antibiotics.&#xD;
&#xD;
          5. Recent vaccination within the last 8 weeks prior to study scree or any study blood&#xD;
             draw.&#xD;
&#xD;
          6. Any known history of liver-related diseases including but not limited to: hepatic&#xD;
             cirrhosis of decompensated chronic liver diseases; clinically active hepatitis B or C&#xD;
             infection as evidenced by clinical jaundice or Grade 2 or higher liver function test&#xD;
             abnormalities; any hepatic impairment, regardless of the graded liver function test&#xD;
             abnormalities.&#xD;
&#xD;
          7. Any known history of gastrointestinal diseases including but not limited to: history&#xD;
             of diarrheal illness requiring the use of anti-motility agents including inflammatory&#xD;
             bowel disease, chronic diarrhea not otherwise specified; history of gastrointestinal&#xD;
             bleeding with hemoglobin below 12.5 g/dL; history of gastric or duodenal ulcers;&#xD;
             inflammatory gastrointestinal disease such as Crohn's disease or ulcerative colitis&#xD;
&#xD;
          8. Any renal disease (eGFR &lt; 90 ml/min) or acute nephritis.&#xD;
&#xD;
          9. Screening hemoglobin below 12.5 g/dL.&#xD;
&#xD;
         10. Screening TSH consistent with hypothyroidism.&#xD;
&#xD;
         11. Significant myocardial disease (current myocarditis or reduced left ventricular&#xD;
             ejection fraction below the lower limit of normal) or diagnosed coronary artery&#xD;
             disease.&#xD;
&#xD;
         12. Significant respiratory disease requiring oxygen.&#xD;
&#xD;
         13. Diabetes or current hypothyroidism.&#xD;
&#xD;
         14. Participants of reproductive potential or breastfeeding. Women of childbearing&#xD;
             potential must have a negative serum pregnancy test at screening. All participants of&#xD;
             childbearing potential must agree to use a double-barrier method of contraception&#xD;
             throughout the study period and up to 90 days after the last dose of kansui.&#xD;
&#xD;
         15. Exposure to any immunomodulatory drug (including maraviroc) in the16 weeks prior to&#xD;
             study.&#xD;
&#xD;
         16. Prior or current use of experiment agents used with the intent to perturb the HIV-1&#xD;
             viral reservoir.&#xD;
&#xD;
         17. History of seizures, psychosis, abnormal electroencephalogram or brain damage with&#xD;
             significant persisting neurological deficit&#xD;
&#xD;
         18. Positive test for tuberculosis by either skin test (PPD) or blood interferon-gamma&#xD;
             release assay (QuantiFERON).&#xD;
&#xD;
         19. Significant substance use, which in the opinion of the investigator(s), is likely to&#xD;
             interfere with the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sulggi A Lee, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adam M Spivak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cary DC, Fujinaga K, Peterlin BM. Euphorbia Kansui Reactivates Latent HIV. PLoS One. 2016 Dec 15;11(12):e0168027. doi: 10.1371/journal.pone.0168027. eCollection 2016.</citation>
    <PMID>27977742</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang P, Lu P, Qu X, Shen Y, Zeng H, Zhu X, Zhu Y, Li X, Wu H, Xu J, Lu H, Ma Z, Zhu H. Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui. Sci Rep. 2017 Aug 25;7(1):9451. doi: 10.1038/s41598-017-07157-0.</citation>
    <PMID>28842560</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Q, Li W, Huang L, Asada Y, Morris-Natschke SL, Chen CH, Lee KH, Koike K. Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from Euphorbia kansui. Eur J Med Chem. 2018 Aug 5;156:618-627. doi: 10.1016/j.ejmech.2018.07.020. Epub 2018 Jul 19.</citation>
    <PMID>30031972</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Sulggi A. Lee, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

